# GS-0201

Source: https://onco.cc/drugs/gs-0201/  
OnCo record `gs-0201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GS-0201 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

Gilead describes GS-0201 as a PARP1 inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. NCT06167317 is recruiting and tests GS-0201 alone and with sacituzumab govitecan, connecting PARP dependency with TROP-2-directed delivery.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: Gilead describes GS-0201 as a PARP1 inhibitor.

## Sources

- ClinicalTrials.gov NCT06167317: https://clinicaltrials.gov/study/NCT06167317
- Primary publication or sponsor source: https://www.gilead.com/science/pipeline

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06167317/)

---
JSON: https://onco.cc/api/v1/entities/gs-0201.json